The collaboration integrates Nivi’s conversational AI platform, which has already engaged 2.5 million users, with MSD’s expertise in HPV scientific education. By utilizing messaging channels like WhatsApp, the system provides personalized risk assessments and direct referrals to nearby vaccination centers. This approach aims to bypass traditional healthcare barriers in regions where public awareness of HPV and preventative screening remains dangerously low.

Dr. Priya Agrawal, Vice President of Health Equity and Partnerships at MSD, noted that the project is designed to empower individuals who are often missed by conventional education channels. Beyond direct patient support, the AI platform tracks real-time consumer behavior, providing MSD with data to refine its global health equity strategies. Siddhartha Goyal, CEO of Nivi, stated that the partnership signals a shift in how pharmaceutical entities engage with patient needs in emerging markets.

The public health stakes are significant. In 2022, India recorded 127,526 new cervical cancer cases and 79,906 deaths. While Thailand maintains higher screening coverage, all three target countries face a projected increase in disease burden of over 40% by 2040 without intervention. This initiative directly supports the World Health Organization’s goal of having 90% of girls vaccinated against HPV by age 15 by improving vaccine confidence and addressing pervasive information asymmetry.